|
Neoplasm Metastasis
|
0.300 |
GeneticVariation
|
phenotype |
BEFREE |
In tuberous sclerosis (TSC)-associated tumors, mutations in the TSC genes lead to aberrant activation of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway. mTORC1 signaling impacts many biological processes including the epithelial-mesenchymal transition (EMT), which is suggested to promote tumor progression and metastasis in various types of cancer.
|
31207499 |
2019 |
|
Neoplasm Metastasis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
The phosphoinositide 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) pathway is frequently overactivated in cancer, and drives cell growth, proliferation, survival, and metastasis.
|
31244112 |
2019 |
|
Neoplasm Metastasis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
The expressions of PI3K, PKB, and mTOR proteins were associated with T stage, N stage, clinical stage, relapse, and distant metastasis.
|
30582216 |
2019 |
|
Neoplasm Metastasis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
Activation of mTOR promotes tumor growth and metastasis.
|
31277692 |
2019 |
|
Neoplasm Metastasis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
In this study, myeloid cell-specific Raptor knockout (KO) mice were used to determine the roles of mechanistic target of rapamycin complex 1 (mTORC1) in regulating macrophage function from Lewis lung carcinoma (LLC) s.c. tumors and lung tumor metastasis.
|
30665937 |
2019 |
|
Neoplasm Metastasis
|
0.300 |
AlteredExpression
|
phenotype |
BEFREE |
Recently, activation of mTOR pathway independent of KIT signaling was demonstrated in imatinib mesylate naïve malignant GISTs and treatment-resistant metastatic tumors.
|
28777148 |
2019 |
|
Neoplasm Metastasis
|
0.300 |
GeneticVariation
|
phenotype |
BEFREE |
Targeted next generation sequencing (NGS) of MTOR, TSC1 and TSC2 genes in the primary tumor, metastasis and blood of the patient, revealed one inactivating TSC2 mutation (c.2739dup; p.K914*) in the tumor cells.
|
29764404 |
2018 |
|
Neoplasm Metastasis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
PPP2R2D, a regulatory subunit of protein phosphatase 2A, promotes gastric cancer growth and metastasis via mechanistic target of rapamycin activation.
|
29568966 |
2018 |
|
Neoplasm Metastasis
|
0.300 |
GeneticVariation
|
phenotype |
BEFREE |
The metastatic tumor also had an activating MTOR mutation, which may be important for tumor metastasis.
|
30176882 |
2018 |
|
Neoplasm Metastasis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
Accordingly, these cells activate the mammalian target of rapamycin pathway, which is thought to be advantageous for cancer cell metastasis.
|
29399186 |
2018 |
|
Neoplasm Metastasis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
Mammalian target of rapamycin (mTOR) plays a critical role in the regulation of tumor cell motility, invasion and cancer cell metastasis. mTOR consists of two separate multi-protein complexes, mTOR complex (mTORC) 1 and mTORC2.
|
29491094 |
2018 |
|
Neoplasm Metastasis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
This review focuses on the downstream mTOR-regulated processes that are implicated in the "hallmarks" of cancer with focus on mTOR's involvement in proliferative signalling, metabolic reprogramming, angiogenesis and metastasis.
|
29301334 |
2018 |
|
Neoplasm Metastasis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
We propose that the AKT-mTOR-STAT3 axis is a potential therapeutic target for blocking the invasion and metastasis of breast cancers.
|
29212252 |
2017 |
|
Neoplasm Metastasis
|
0.300 |
GeneticVariation
|
phenotype |
BEFREE |
Overexpression of CHKA in HCC cell lines increased their invasiveness, resistance to EGFR inhibitors, and ability to form metastatic tumors in mice by promoting interaction of EGFR with mechanistic target of rapamycin complex 2.
|
28065789 |
2017 |
|
Neoplasm Metastasis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition.
|
27991928 |
2017 |
|
Neoplasm Metastasis
|
0.300 |
AlteredExpression
|
phenotype |
BEFREE |
In cancer tissues, p-mTOR expression was higher in adenocarcinoma than in other types of cancers, in metastatic cancer than in primary cancer, and in the forefront of the infiltrating cancer cells.
|
28831205 |
2017 |
|
Neoplasm Metastasis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
The dysregulated mTOR and PRKA pathway could remodel cell metabolism during the growth and metastasis of cancer in order for the cancer cell to survive the unfavorable microenvironment such as hypoxia and low blood supply.
|
28465145 |
2017 |
|
Neoplasm Metastasis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
This study was conducted to find the impact of genetic variations in the phosphatidylinositol 3-kinase(PI3K)/phosphatase and tensin homologue(PTEN)/v-akt murine thymoma viral oncogene homologue(AKT)/mammalian target of rapamycin(mTOR) pathway on the risk of distant metastasis in NPC.
|
27876891 |
2016 |
|
Neoplasm Metastasis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
Our results indicate that LAL has a critical role in regulating MDSCs' ability to directly stimulate cancer cell proliferation and overcome immune rejection of cancer metastasis in allogeneic mice through modulation of the mTOR pathway, which provides a mechanistic basis for targeting MDSCs to reduce the risk of cancer metastasis.
|
24882582 |
2015 |
|
Neoplasm Metastasis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
Here we review phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR signaling as one of the primary mechanisms for sustaining tumor outgrowth and metastasis, recent advances in the development of mTOR inhibitors, and current studies addressing mTOR activation/inhibition in colorectal cancer (CRC).
|
24393708 |
2014 |
|
Neoplasm Metastasis
|
0.300 |
Biomarker
|
phenotype |
RGD |
mTOR inhibitor RAD001 promotes metastasis in a rat model of pancreatic neuroendocrine cancer.
|
23149918 |
2013 |
|
Neoplasm Metastasis
|
0.300 |
AlteredExpression
|
phenotype |
BEFREE |
Loss of p(Ser2448)-mTOR expression was linked to tumor metastasis (p = 0.0275) in ERG-fusion-positive cancers only.
|
22886792 |
2013 |
|
Neoplasm Metastasis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
Lymphangioleiomyomatosis (LAM) is a destructive lung disease of women associated with the metastasis of tuberin-null cells with hyperactive mammalian target of rapamycin complex 1 (mTORC1) activity.
|
23983265 |
2013 |
|
Neoplasm Metastasis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
The mammalian target of rapamycin (mTOR) kinase, a downstream effector of PI3K/Akt signaling, regulates tumorigenesis and metastasis of CRCs, indicating that mTOR inhibition may have therapeutic potential.
|
22696593 |
2012 |
|
Neoplasm Metastasis
|
0.300 |
Biomarker
|
phenotype |
BEFREE |
Only cytoplasmic phospho-mTOR showed independent prognostic significance (P = .029) and fidelity between primary RCCs and their matched metastases (P = .004).
|
20830770 |
2011 |